Literature DB >> 15917514

Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region.

Mark T McCammon1, John S Gillette, Derek P Thomas, Srinivas V Ramaswamy, Ishmael I Rosas, Edward A Graviss, Jan Vijg, Teresa N Quitugua.   

Abstract

Denaturing gradient gel electrophoresis (DGGE) was used to probe for mutations associated with pyrazinamide (PZA) resistance in the pncA gene of Mycobacterium tuberculosis. DGGE scans for mutations across large regions of DNA and rivals sequencing in its ability to detect DNA alterations. Specific mutations can often be recognized by their characteristic denaturation pattern, which serves as a molecular fingerprint. Five PCR target fragments were designed to scan for DNA alterations across 600 bp of pncA in 181 M. tuberculosis isolates from patients residing in the U.S-Mexico border states of Texas and Tamaulipas, respectively. A region of pncA was observed with a high GC content and a melting temperature approaching 90 degrees C that was initially refractory to denaturation, and a DGGE target fragment was specifically designed to detect mutations in this region. DGGE detected pncA mutations in 82 of 83 PZA-resistant isolates. By contrast, only 1 of 98 PZA-susceptible isolates harbored a detectable DNA alteration. The pncA gene was sequenced from 41 isolates, and 32 DNA alterations in 32 PZA-resistant isolates were identified, including 11 new mutations. DGGE also detected nine isolates whose susceptibility to PZA appeared to be incorrect, and DNA sequencing confirmed these apparent errors in drug susceptibility testing. These results demonstrate the power and usefulness of DGGE in detecting mutations associated with PZA resistance in M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917514      PMCID: PMC1140546          DOI: 10.1128/AAC.49.6.2210-2217.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia.

Authors:  H J Marttila; M Marjamäki; E Vyshnevskaya; B I Vyshnevskiy; T F Otten; A V Vasilyef; M K Viljanen
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  M Mestdagh; P A Fonteyne; L Realini; R Rossau; G Jannes; W Mijs; K A De Smet; F Portaels; E Van den Eeckhout
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Detection of rifampin resistance in Mycobacterium tuberculosis by double gradient-denaturing gradient gel electrophoresis.

Authors:  P Scarpellini; S Braglia; P Carrera; M Cedri; P Cichero; A Colombo; R Crucianelli; A Gori; M Ferrari; A Lazzarin
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru.

Authors:  P Escalante; S Ramaswamy; H Sanabria; H Soini; X Pan; O Valiente-Castillo; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

Review 5.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

6.  pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Authors:  S J Cheng; L Thibert; T Sanchez; L Heifets; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA.

Authors:  N Lemaitre; W Sougakoff; C Truffot-Pernot; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China.

Authors:  L Hou; D Osei-Hyiaman; Z Zhang; B Wang; A Yang; K Kano
Journal:  Epidemiol Infect       Date:  2000-04       Impact factor: 2.451

9.  Simultaneous identification and typing of multi-drug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB.

Authors:  T J Brown; Ö Tansel; G L French
Journal:  J Med Microbiol       Date:  2000-07       Impact factor: 2.472

10.  Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis.

Authors:  Mark T McCammon; John S Gillette; Derek P Thomas; Srinivas V Ramaswamy; Edward A Graviss; Barry N Kreiswirth; Jan Vijg; Teresa N Quitugua
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

View more
  10 in total

1.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

2.  Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China.

Authors:  Yaoju Tan; Zuqiong Hu; Tianyu Zhang; Xingshan Cai; Haobin Kuang; Yanwen Liu; Junyu Chen; Feng Yang; Ke Zhang; Shouyong Tan; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

Review 3.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 4.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

Review 5.  Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Sarah M Ramirez-Busby; Faramarz Valafar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

6.  Detection of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis using denaturing gradient gel electrophoresis.

Authors:  Mark T McCammon; John S Gillette; Derek P Thomas; Srinivas V Ramaswamy; Edward A Graviss; Barry N Kreiswirth; Jan Vijg; Teresa N Quitugua
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Sheen; Miguel Quiliano; Andrés Gutierrez; Robert H Gilman
Journal:  Infect Genet Evol       Date:  2009-12-04       Impact factor: 3.342

8.  Sequence polymorphisms in a surface PPE protein distinguish types I, II, and III of Mycobacterium avium subsp. paratuberculosis.

Authors:  Tanya A Griffiths; Kevin Rioux; Jeroen De Buck
Journal:  J Clin Microbiol       Date:  2008-02-13       Impact factor: 5.948

9.  Rapid detection of rpoB mutations in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresis.

Authors:  Jun Li; Jiaojiao Xin; Liyuan Zhang; Longyan Jiang; Hongcui Cao; Lanjuan Li
Journal:  Int J Med Sci       Date:  2012-01-11       Impact factor: 3.738

10.  Base-calling algorithm with vocabulary (BCV) method for analyzing population sequencing chromatograms.

Authors:  Yuri S Fantin; Alexey D Neverov; Alexander V Favorov; Maria V Alvarez-Figueroa; Svetlana I Braslavskaya; Maria A Gordukova; Inga V Karandashova; Konstantin V Kuleshov; Anna I Myznikova; Maya S Polishchuk; Denis A Reshetov; Yana A Voiciehovskaya; Andrei A Mironov; Vladimir P Chulanov
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.